Observational Trial of Antibiotic-Coated Central Venous Catheters in Critically Ill Pediatric Patients

Background: Catheter-associated bloodstream infections (CABSI) are among the most common and serious adverse events experienced by critically ill children. Randomized trials have demonstrated that the use of central venous catheters (CVC) coated with antiseptic solutions reduces rates of CABSI in adult patients; however, their efficacy in children has not been evaluated. Objective: To compare the incidence of CABSI, rate of complications, and microbiology of infection in critically ill children treated with antibiotic-coated or noncoated CVC (NC-CVC). Methods: A prospective observational trial was conducted in the pediatric intensive care unit (PICU) during a 13-month period. A minocycline-rifampin–coated CVC (MR-CVC) or NC-CVC was placed by PICU physicians who nonpreferentially selected CVC type. Results: We studied the outcomes associated with the first CVC placed in 225 patients, including 69 MR-CVC and 156 NC-CVC. Patients who received MR-CVC, as compared with NC-CVC, were similar in gender, age, and severity of illness at time of PICU admission. The incidence density of CABSI did not vary by catheter type [MR-CVC: 7.53 per 1000 catheter-days (95% confidence interval 2.05–19.17); NC-CVC: 8.64 CABSI per 1000 catheter-days (95% confidence interval 3.74–16.96)]. However, the median time to infection in children with MR-CVC was 3-fold longer than in children with NC-CVC [18 versus 5 days (P = 0.053)]. No difference was seen in the incidence of complications, including thrombosis and catheter site reaction, between MR- and NC-CVC. No significant difference was observed in the types of organisms recovered from patients with MR- and NC-CVC. Conclusions: The use of MR-CVC significantly delayed the onset of CABSI in PICU patients. Larger, randomized trials are needed to better define potential differences in the incidence of CABSI, rate of complications, and microbiology of infection among pediatric patients treated with antiseptic-coated CVC and NC-CVC.

[1]  C. Hollenbeak,et al.  Attributable Cost of Nosocomial Primary Bloodstream Infection in Pediatric Intensive Care Unit Patients , 2005, Pediatrics.

[2]  J. Rello,et al.  Benefits of minocycline and rifampin-impregnated central venous catheters , 2004, Intensive Care Medicine.

[3]  D. Maki,et al.  Are antimicrobial-impregnated catheters effective? Don't throw out the baby with the bathwater. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  M. Rupp,et al.  Prevention of central venous catheter-related bloodstream infections , 2004 .

[5]  G. Samonis,et al.  Clinical Experience With Minocycline and Rifampin-Impregnated Central Venous Catheters in Bone Marrow Transplantation Recipients: Efficacy and Low Risk of Developing Staphylococcal Resistance , 2003, Infection Control & Hospital Epidemiology.

[6]  S. Tambe,et al.  In vitro evaluation of the risk of developing bacterial resistance to antiseptics and antibiotics used in medical devices. , 2001, The Journal of antimicrobial chemotherapy.

[7]  A. Slonim,et al.  The costs associated with nosocomial bloodstream infections in the pediatric intensive care unit , 2001, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[8]  L. Mermel,et al.  New technologies to prevent intravascular catheter-related bloodstream infections. , 2001, Emerging infectious diseases.

[9]  A. Costarino,et al.  The impact of adverse patient occurrences on hospital costs in the pediatric intensive care unit , 2001, Critical care medicine.

[10]  Sanjay Saint,et al.  Prevention of Intravascular Catheter-Associated Infections , 2001 .

[11]  ohn,et al.  A COMPARISON OF TWO ANTIMICROBIAL-IMPREGNATED CENTRAL VENOUS CATHETERS , 2000 .

[12]  S. Saint,et al.  Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection. , 1999, JAMA.

[13]  D. Morck,et al.  Antimicrobial durability and rare ultrastructural colonization of indwelling central catheters coated with minocycline and rifampin. , 1998, Critical care medicine.

[14]  Rabih Darouiche,et al.  Central Venous Catheters Coated with Minocycline and Rifampin for the Prevention of Catheter-Related Colonization and Bloodstream Infections , 1997, Annals of Internal Medicine.

[15]  A. Gabrielli,et al.  Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. , 1997, Annals of internal medicine.

[16]  F. Moler,et al.  Percutaneous central venous catheterization in a pediatric intensive care unit: a survival analysis of complications. , 1990, Critical care medicine.

[17]  B. Yangco,et al.  CDC definitions for nosocomial infections. , 1989, American journal of infection control.

[18]  J M Hughes,et al.  CDC definitions for nosocomial infections, 1988. , 1988, American journal of infection control.